ALNY — Alnylam Pharmaceuticals Inc · catalysts, narrative & risks

Executive Summary
As of 30 July 2026, Alnylam Pharmaceuticals (ticker ALNY) remains a differentiated leader in the RNA‑i space, with a robust pipeline that spans cardiovascular, neurologic, and metabolic disorders. The company’s stock closed at $312.79 on 3 July 2026 [1] and has since posted a 6.3 % gain following its second‑quarter earnings announcement on 14 July 2026 [13]. Analysts have adjusted price targets (H.C. Wainwright and TipRanks) and reaffirmed a “Buy” rating, citing the firm’s progress in Phase III trials, upcoming manufacturing investment, and regulatory milestones [10], [12].

---

1. Key RECENT Catalysts (Last ~1–3 Months)